Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

401 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Immunotherapy for Graves' ophthalmopathy.
Salvi M. Salvi M. Curr Opin Endocrinol Diabetes Obes. 2014 Oct;21(5):409-14. doi: 10.1097/MED.0000000000000097. Curr Opin Endocrinol Diabetes Obes. 2014. PMID: 25105999 Review.
Thyroid ophthalmopathy.
Salvi MG, Neri F. Salvi MG, et al. Curr Ther Endocrinol Metab. 1994;5:77-81. Curr Ther Endocrinol Metab. 1994. PMID: 7704806 No abstract available.
Teprotumumab for Thyroid-Associated Ophthalmopathy.
Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, Antonelli A, Salvi M, Goldberg RA, Gigantelli JW, Couch SM, Shriver EM, Hayek BR, Hink EM, Woodward RM, Gabriel K, Magni G, Douglas RS. Smith TJ, et al. Among authors: salvi m. N Engl J Med. 2017 May 4;376(18):1748-1761. doi: 10.1056/NEJMoa1614949. N Engl J Med. 2017. PMID: 28467880 Free PMC article. Clinical Trial.
Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone.
Antonelli A, Ferrari SM, Fallahi P, Piaggi S, Paolicchi A, Franceschini SS, Salvi M, Ferrannini E. Antonelli A, et al. Among authors: salvi m. Metabolism. 2011 Feb;60(2):277-83. doi: 10.1016/j.metabol.2010.02.002. Epub 2010 Mar 6. Metabolism. 2011. PMID: 20206950
401 results